Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

ClinicalTrials.gov ID: NCT07197944

Public ClinicalTrials.gov record NCT07197944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Study identification

NCT ID: NCT07197944
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Zealand Pharma; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Short Bowel Syndrome

Interventions

Glepaglutide Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 10, 2026
Primary completion: Oct 22, 2028
Completion: Feb 27, 2032
Last update posted: Aug 11, 2026

2026 – 2032

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
The University of Chicago Medicine	Chicago	Illinois	60637-1443	Recruiting
Washington University Center for Advanced Medicine	St Louis	Missouri	63110	Recruiting
Lied Transplant Center at Nebraska Medical Center	Omaha	Nebraska	68105	Recruiting
New York Presbyterian Hospital-Columbia University Medical Center	New York	New York	10032	Not yet recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07197944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07197944 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →